Resonance Medicine

Resonance Medicine is a biotechnology company pioneering the development of engineered proteases as a novel class of therapeutics. The company's platform focuses on designing highly specific proteases that can selectively degrade disease-causing proteins, particularly those located on the cell surface or in the extracellular space. This approach aims to overcome the limitations of traditional protein degradation technologies, such as PROTACs, which primarily target intracellular proteins. Resonance is currently advancing a pipeline of candidates for applications in immunology, inflammation, and oncology. The company is headquartered in New York and is backed by ARCH Venture Partners. By leveraging advanced protein engineering, Resonance seeks to create programmable enzymes that can address previously undruggable targets.